Does the Type of BCR/ABL Junction Predict the Survival of Patients with Ph¹-Positive Chronic Myeloid Leukemia?

Alfonso Zaccaria Centro di Genetica e Citogenetica Oncologica, Istituto di Ematologia “Lorenzo e Ariosto Seragnoli,” Centra Interdipartimentale per la Ricerca sul Cancro “G. Prodi” dell'Universita degli Studi, Bologna

Giovanni Martinelli Centro di Genetica e Citogenetica Oncologica, Istituto di Ematologia “Lorenzo e Ariosto Seragnoli,” Centra Interdipartimentale per la Ricerca sul Cancro “G. Prodi” dell'Universita degli Studi, Bologna

Nicoletta Testoni Centro di Genetica e Citogenetica Oncologica, Istituto di Ematologia “Lorenzo e Ariosto Seragnoli,” Centra Interdipartimentale per la Ricerca sul Cancro “G. Prodi” dell'Universita degli Studi, Bologna

Eliana Zuffa Centro di Genetica e Citogenetica Oncologica, Istituto di Ematologia “Lorenzo e Ariosto Seragnoli,” Centra Interdipartimentale per la Ricerca sul Cancro “G. Prodi” dell'Universita degli Studi, Bologna

Patrizia Farabegoli Centro di Genetica e Citogenetica Oncologica, Istituto di Ematologia “Lorenzo e Ariosto Seragnoli,” Centra Interdipartimentale per la Ricerca sul Cancro “G. Prodi” dell'Universita degli Studi, Bologna

Domenico Russo Cattedra di Ematologia, Universita di Udine, Italia

Angelo Guerrasio Dipartimento di Scienze Biomediche ed Oncologia Umana Sezione Clinica, Universitá di Torino, Italia

Sante Tura Centro di Genetica e Citogenetica Oncologica, Istituto di Ematologia “Lorenzo e Ariosto Seragnoli,” Centra Interdipartimentale per la Ricerca sul Cancro “G. Prodi” dell'Universita degli Studi, Bologna

show all

Abstract

The prognostic value of the site of DNA rearrangement within the M-BCR on chromosome 22 or of the type of transcript has been debated in the last years. The majority of the studies do not support the hypothesis of a predictive value of such molecular parameters. Results coming from a multicentric, prospective trial, based on α-IFN therapy, seem to indicate a better karyotypic response in 3′ rearranged patients. The possibility of evoking a cytotoxic immune response directed towards peptides originating from each of the different BCR/ABL junctions constitute an important challenge for the future.

Key Words:

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Does the Type of BCR/ABL Junction Predict the Survival of Patients with Ph¹-Positive Chronic Myeloid Leukemia?

Information for

Open access

Opportunities

Help and information

Does the Type of BCR/ABL Junction Predict the Survival of Patients with Ph1-Positive Chronic Myeloid Leukemia?

Abstract

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature

Does the Type of BCR/ABL Junction Predict the Survival of Patients with Ph¹-Positive Chronic Myeloid Leukemia?